Loading...

VTYX VENTYX BIOSCIENCES INC Product Launches 8-K Filing

VNTY

VTYX

VENTYX BIOSCIENCES INC

(VTYX)

2024 8-K

Show Summary

Show Summary

Financial Statements

Investor Update

Q3 Financial Results

Equity Financing

Earnings Reports

Annual Meeting of Stockholders

Preclinical Data Announcement

Appointment of COO

Earnings Reports

Resignation of Officer

Stock Purchase Agreement

Financial Results Announcement

Costs Associated with Exit ...

Financial Results Announcement

Earnings Reports

Financial Results Announcement

Sublease Agreement

Annual Meeting of Stockholders

Earnings Reports

Financial Results Announcement

Investor R&D Day

Management Changes

External Links:

Ventyx Biosciences announced preclinical data on its CNS-penetrant NLRP3 inhibitor, VTX3232, in murine diet-induced obesity models, showing positive results and plans for Phase 2 trials.

AI Assistant

VENTYX BIOSCIENCES INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.